OPRX OptimizeRx Corp

OptimizeRx to Present at RBC Capital Markets Global Virtual Healthcare Conference on May 19, 2021

OptimizeRx to Present at RBC Capital Markets Global Virtual Healthcare Conference on May 19, 2021

ROCHESTER, Mich., May 11, 2021 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will participate in RBC Capital Markets Global Healthcare Virtual Conference.

Will Febbo, OptimizeRx’s CEO will participate in a fireside chat format at 8:00 a.m. ET on Wednesday, May 19, 2021.

The live presentation will be available at .

About OptimizeRx

OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.

For more information, follow the company on ,  or visit . 

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and in section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

OptimizeRx Contact

Doug Baker, CFO

Tel (248) 651-6568 x807

Media Relations Contact 

Maira Alejandra, Media Relations Manager

Tel (754) 245-7070 

Investor Relations Contact

Ashley Robinson

LifeSci Advisors, LLC



EN
11/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Appoints Mary Varghese Presti to Board of Directors

OptimizeRx Appoints Mary Varghese Presti to Board of Directors Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Mary Varghese Presti to its Board of Directors. The appointment of Varghese Presti as an independent ...

 PRESS RELEASE

UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 F...

UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results -   Q4 revenue of $32.2 million-   Q4 gross profit increased 9% year-over-year to $24.1 million-   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively-   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million-   Paid off an incremental $2 million in principal from term loan during Q4-   OptimizeRx's Board authorizes a $10 million share repurchase program  WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx C...

 PRESS RELEASE

OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial ...

OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results -   Q4 revenue of $32.2 million-   Q4 gross profit increased 9% year-over-year to $24.1 million-   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively-   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million-   Paid off an incremental $2 million in principal from term loan during Q4-   OptimizeRx's Board authorizes a $10 million share repurchase program  WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the...

 PRESS RELEASE

OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Co...

OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. Optimiz...

 PRESS RELEASE

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity R...

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectiveness WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data an...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch